Check out Nature Communications Editors' Highlights that showcase the 50 best papers recently published in micorbiology and infectious diseases nature.com/collections/je…

AAHI take a pragmatic and creative approach to develop equitably accessible TB vaccines, recognizing that a vaccine makes little or no impact is it is unaffordable and cannot be distributed to people who need it. #WorldTBDay Read more - bit.ly/3z38sW7

One week away until the World Vaccine Congress Washington #WVCDC! Check out AAHI's intro video and connect with us directly or stop by booth #805 to learn more about how we develop accessible and equitable health solutions. World Vaccine Congress bit.ly/42I06kv

The use of shark-derived squalene as a vaccine product is not sustainable and impacts shark welfare. Researchers from AAHI have found a way to create analogues of shark-derived squalene, with a helping hand from yeast fermentation. Technology Networks technologynetworks.com/vaccines/blog/…

Sm-p80 - SchistoShield®️ is a defined molecular #vaccine for intestinal #schistosomiasis. This vaccine💉 is based on a recombinant antigen, Sm-p80, that is easily accessible to the host's immune system. Now in phase 1 clinical trials. #BeatSchisto #WIW2023 clinicaltrials.gov/ct2/show/NCT05…

AAHI is committed to developing safe and durable #adjuvant intranasal vaccines with the support of the NIH, 3M, and other partners. Katelyn Jetelina & Edward Nirenberg 🇺🇦 yourlocalepidemiologist.substack.com/p/hype-or-hope…

Made possible by #adjuvant technology!

“Our efforts should shift to measures required for facing Covid-19 as a long-term cause of human illness, suffering and death, not a short-term catastrophe.” nytimes.com/2023/05/09/opi…

Tardigrades can be dried, frozen, boiled, irradiated-and still survive. Scientists study their secrets to make medicines that don’t require refrigeration. That would be a gamechanger for hot climates & places w/ unreliable electricity UWyo News AAHI leaps.org/tardigrades/

Dr Will Lykins AAHI presenting talk on Pre-clinical optimisation of adjuvant formulation, route and regimen of SARS-SoV-2 subunit vaccine at MEDICONmm/mvads_2023 in Copenhagen

As pandemic raged, global south lacked vaccines. Never again, researchers vow. washingtonpost.com/health/2023/07…

Latest from our ⁦Texas Children's⁩ vaccine center in collaboration with ⁦AAHI⁩ in Seattle WA Choice of Adjuvant and Antigen Composition Alters the Immunogenic Profile of a SARS-CoV-2 Subunit Vaccine frontiersin.org/articles/10.33…

Congratulations Curevo team on recent human clinical trial results demonstrating its #shingles vaccine candidate, CRV-101, elicits a 100% vaccine response rate. We are thrilled to support the team by providing our SLA-SE #adjuvant formulation, a critical component of CRV-101.

Our next #wvcdc interview is now live, featuring Candice Decaire of AAHI! Hear about the team's proposal for a #network of innovators. #vaccinenation #vaccine #technology #globalhealth #innovation #aahi vaccinenation.org/global-health/…